Amgen 20170596 An Open Label Phase 2 Study of Carfilzomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

January 11, 2019
https://clinicaltrials.gov/ct2/show/NCT03512353
Cancer - Myeloma
Principal Investigator: Vrushali S Dabak, MD
myeloma, carfilzomib
Accepting Participants
(313)916-1784